By InvitationNot Applicable

Clinical and Genetic Aspects of Fetuses With Sex-chromosome Disorders

Denmark120 participantsStarted 2024-01-01

Plain-language summary

To conduct a comprehensive clinical investigation of electively aborted fetuses with sex chromosome disorders and their placentas, in parallel with analyses of epigenetic alterations and changes in gene expression in these fetuses and their placentas, with the aims to: 1. delineate how variations in sex chromosome number affect the epigenetic and genetic mechanisms regulating gene expression in the placenta and in multiple fetal tissues in fetuses with sex chromosome disorders; 2. identify the epigenetic and genetic mechanisms and placental and fetal alterations that underlie the phenotypic manifestations observed in fetuses with sex chromosome disorders.

Who can participate

Age range11 Weeks – 22 Weeks

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria cases: * Age ≥18 years * Fetuses with genetically verified sex chromosome disorders * Gestational age between 11+0 and 22+6 at the time of abortion or at delivery due to intrauterine fetal death * Written informed consent Inclusion criteria cases: * Age ≥18 years * No known sex chromosome disorder or other genetic disorder in the fetus * No known fetal malformations * Fetal growth within the normal range * Gestational age between 11+0 and 22+6 at the time of abortion

What they're measuring

DNA methylation profile

Timeframe: 5 years

Gene expression profile

Timeframe: 5 years

Trial details

NCT IDNCT07304193

SponsorUniversity of Aarhus

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-12-31

View on ClinicalTrials.gov More Sex Chromosome Disorders trials